868689-63-8

Basic information

• Product Name: (S)-4-(tert-Butoxycarbonyl)morpholine-2-carboxylic acid
• Synonyms: (S)-4-(tert-butoxycarbonyl)morpholine-2-carboxylic acid;(2S)-2,4-Morpholinedicarboxylic acid 4-(1,1-dimethylethyl) ester;(S)-N-Boc-2-morpholinecarboxylic acid;(S)-4-Boc-morpholine-2-carboxylic acid;(S)-N-Boc-morpholine-2-carboxylic acid;(2S)-4-[(tert-butoxy)carbonyl]Morpholine-2-carboxylic acid;868689-63-8;(S)-4-(tert-butoxycabonyl)morpholine-2-carboxylic acid
• CAS NO: 868689-63-8
• Molecular Formula: C₁₀H₁₇NO₅
• Molecular Weight: 231.25
• Mol File: 868689-63-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 127-134 ºC
• Boiling Point: 369.5 °C at 760 mmHg
• Flash Point: 177.3 °C
• Appearance: /
• Density: 1.230
• Vapor Pressure: 1.8E-06mmHg at 25°C
• Refractive Index: 1.492
• Storage Temp.: 2-8°C
• PKA: 3.25±0.20(Predicted)
• CAS DataBase Reference: (S)-4-(tert-Butoxycarbonyl)morpholine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-(tert-Butoxycarbonyl)morpholine-2-carboxylic acid(868689-63-8)
• EPA Substance Registry System: (S)-4-(tert-Butoxycarbonyl)morpholine-2-carboxylic acid(868689-63-8)

Safety Data

• Hazardous Substances Data: 868689-63-8(Hazardous Substances Data)

Usage

Uses

(S)-4-(tert-Butoxycarbonyl)morpholine-2-carboxylic Acid can be used for cancer treatment.

InChI:InChI=1/C10H17NO5/c1-10(2,3)16-9(14)11-4-5-15-7(6-11)8(12)13/h7H,4-6H2,1-3H3,(H,12,13)/t7-/m0/s1

Upstream product

• 135065-76-8 tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 1030837-49-0 (S)-4-benzyl-morpholine-2-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 135065-76-8 tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 847805-31-6 (S)-(+)-2-formylmorpholine-4-carboxylic acid tert-butyl ester 
• 1415794-22-7 C₁₁H₂₂N₂O₃ 
• 500702-97-6 benzyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 

Relevant articles and documents

DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF

The present invention relates to a dihydropyrimidine compound having an antiviral activity, a pharmaceutical composition comprising same, a preparation method therefor and the uses thereof in the prevention or treatment of viral diseases including, but no

Design and synthesis of reboxetine analogs morpholine derivatives as selective norepinephrine reuptake inhibitors

As part of a discovery effort aimed at identifying novel norepinephrine reuptake inhibitors (NRIs), a number of substituted morpholines were designed and synthesized. The target compounds contain vicinal stereogenic centers, and the program was greatly facilitated by the adoption of efficient synthetic routes which allowed for the late stage incorporation of structural and physicochemical diversity into the targets. Structure-activity relationships were developed by optimizing individual ring components of the structure for NRI potency and for selectivity against other monoamine reuptake transporters. Several novel morpholine derivatives with a potent and selective NRI profile are described.

Substituted morpholine compounds for the treatment of central nervous system disorders

This invention relates to compounds of the formulae I wherein R1-R8, A, X, and Z are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.